Clinical Report: Retinal Physician Welcomes Diana V. Do, MD, as New Editor in Chief
Overview
Diana V. Do, MD, has been appointed as the new editor in chief of Retinal Physician, succeeding Peter K. Kaiser, MD. Dr. Do aims to enhance the journal's digital presence and global reach while continuing to provide high-quality content for retina specialists.
Background
The appointment of a new editor in chief for a prominent journal like Retinal Physician is significant for the retina subspecialty, as it influences the dissemination of clinical knowledge and advancements. Dr. Do's extensive experience in clinical care and academic research positions her to lead the journal effectively. This transition comes at a time when the retina field is rapidly evolving, necessitating up-to-date resources for specialists.
Data Highlights
No numerical or trial data presented in the article.
Key Findings
- Diana V. Do, MD, is the new editor in chief of Retinal Physician.
- Dr. Do succeeds Peter K. Kaiser, MD, who served for 12 years.
- Under Dr. Kaiser, the journal became a trusted resource for retina specialists.
- Dr. Do plans to expand the journal's digital presence and global reach.
- The journal publishes 9 times per year, covering key topics in retinal care.
Clinical Implications
The leadership change in Retinal Physician may influence the direction of clinical guidelines and research dissemination in the retina field. Specialists can expect continued high-quality content that reflects the latest advancements in patient care and treatment strategies.
Conclusion
Dr. Do's appointment marks a new chapter for Retinal Physician, with a commitment to enhancing the journal's role as a vital resource for retina specialists worldwide.
References
- Diana V. Do, MD, Retinal Physician, 2023 -- Retinal Physician Welcomes Diana V. Do, MD, as New Editor in Chief
- Retinal Physician — Thankful
- New Retinal Physician — FROM THE EDITOR
- Retinal Physician — Upfront
- AAO Preferred Practice Patterns
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials - PubMed
- Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months | Ophthalmology | JAMA Ophthalmology | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.